Bicyclic androgen and progesterone receptor modulator compounds and methods

A compound having the formula:

• wherein:
• R1 and R2 are each independently selected from the group of COR3, CSR3, SO2R3, NO, NR3R4, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 haloalkyl, C2-C8 haloalkenyl, C2-C8 haloalkynyl, C1-C8 heteroalkyl, C2-C8 heteroalkenyl, C2-C8 heteroalkynyl, (CH2)nR3A, aryl, and heteroaryl, wherein the aryl, and heteroaryl are optionally substituted with F, Cl, Br, I, OH, OR3, NR3R4, CN, NO2, SR3, SO2R3, SO2R3, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 heteroalkyl;
• or
• R1 and R2 taken together form a three- to nine-membered alkyl, alkenyl, heteroalkyl, or heteroalkenyl nonaromatic ring, wherein the alkyl, alkenyl, heteroalkyl, or heteroalkenyl ring are optionally substituted with F, Cl, Br, I, OH, OR3, NR3R4, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 heteroalkyl;
• R3 is selected from the group of C1-C8 alkyl, C2-C8 alkenyl, C2-C9 alkynyl, C1-C8 haloalkyl, and C1-C8 heteroalkyl;
• R3A is aryl or heteroaryl, wherein the aryl and heteroaryl is optionally substituted with halogen, CN, NO2, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 heteroalkyl;
• R4 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 heteroalkyl;
• R5 is selected from the group of hydrogen, F, Cl, Br, I, OR3, and C1-C4 alkyl;
• R6 is selected from the group of F, Cl, Br, I, CH3, CF3, CHF2, CFH2, CN, CF2Cl, CF2OR3, OR3, SR3, SO2R3, SO2R3, CO2R3, NR3R4, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C1-C4 heteroalkyl, C2-C4 heteroalkenyl, and C2-C4 heteroalkynyl;
• R7 is selected from the group of hydrogen, F, Cl, Br, I, CN, OH, OR3, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 heteroalkyl;
• R8 is hydrogen or halogen;
• R9 is selected from the group of hydrogen, F, Br, Cl, I, OH, OR3, NR3R4, SR3, SO2R3, SO2R3, C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 heteroalkyl;
• R10 is selected from the group of:
• R16 is selected from the group of hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 heteroalkyl, CH2R3A, aryl, heteroaryl, COR17, CO2R17, and CONR17R17;
• R17 is selected from the group of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 heteroalkyl;
• R24 is hydrogen, OH or OR3;
• R25 and R30 are each independently selected from the group of hydrogen, F, Cl, Br, I, OH, OR3, NR3R4, SR3, SO2R3, SO2R3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, C2-C6 alkynyl and C2-C6 alkenyl, wherein the alkyl, haloalkyl, and heteroalkyl are optionally substituted with F, Cl, Br, I, OR3, NR3R4, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, aryl or heteroaryl, and wherein the aryl and heteroaryl are optionally substituted with F, Cl, Br, I, CN, NO2, OH, OCH3, CF3 or C1-C4 alkyl;
• or
• R26 through R29 are each independently selected from the group of hydrogen, F, Cl, Br, I, OH, OR3, NR3R4, SR3, SOR3, SO2R3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, C2-C6 alkynyl and C2-C6 alkenyl;
• or
• any two of R25 R26, R27, R28, R29 and R30 taken together form a three to seven-membered alkyl or alkenyl or nonaromatic heteroalkyl ring;
• or
• any four of R25, R26, R27, R28, R29 and R30 taken together form a fused aromatic ring;
• X is NR16;
• Y is selected from the group of O, S, NR3, NOR3 and CR3R4;
• Z is selected from the group of O, S, NR3, C═O, and CR25R26;
• or
• Z is two hydrogens;
• and n is 1, 2 or 3;
• and pharmaceutically acceptable salts thereof.